Benoit T
@Tessoulin_B
Followers
31
Following
74
Media
1
Statuses
27
M.D. in Hematology, Nantes University Hospital Ph.D. in Biology, Nantes University, School of Medicine Medical care & Surf!
Joined October 2016
[Journées du LYSA] 📸 Retour en image sur la session Lymphome à cellules du Manteau Avec Morgane Cheminant, Clement Bailly, Steven Le Gouill, Yannick Le Bris, Benoit Tessoulin et Olivier Hermine #LYSAToulouse25 #LYSA #lymphome #lymphoma #rechercheclinique #research
0
1
1
[Journées du LYSA] 📸 Retour en images sur la session @AssoELLyE « Plus loin, ensemble » avec Clotilde Genon et Franck Fontenay #LYSAToulouse25 #ELLYE #FranceLymphomeEspoir #lymphome #lymphoma #rechercheclinique
0
1
0
Honored to share our newly published manuscript https://t.co/HrqUuNK4CM which demonstrates that circulating tumor DNA (ctDNA) by PhasED-Seq offers the most precise definition of remission after frontline therapy for patients with large B-cell lymphoma (LBCL) out now in @JCO_ASCO.
ascopubs.org
Journal of Clinical Oncology (JCO) is a high-impact, peer-reviewed medical journal that publishes significant clinical oncology research along with editorials, reviews, and other works that relate to...
4
23
73
Do you remember the vigorous April 2023 discussion after #ODAC vote & #FDA approval of #polatuzumab for #DLBCL & #HGBCL? Well, with @ac_palmer & Dave Kurtz, we now tackle this more through meta-analysis @NEJM… 1/n https://t.co/wzvOLyoZuX
nejm.org
Analysis of previous trials of polatuzumab vedotin for diffuse large B-cell lymphoma showed that the drug was more effective for tumors of one subtype (activated B cell) than those of another subty...
5
45
123
Print version out this week in @CD_AACR ! Looking forward to seeing everyone at @icmlugano @AACR next week!
At the #ASCO23 #Lymphoma Session? ICYMI in @CD_AACR: Tracing Founder Mutations in Circulating & Tissue-resident #FollicularLymphoma Precursors by @schroersmartin Joanne Soo @gabriel_brisou @FSchererMD Bertrand Nadel @SRoulland @max_diehn @AshAlizadeh et al https://t.co/TEIj4kRyFB
0
4
13
Pleased to announce that our review of molecular monitoring in lymphoma is now open access, with @AshAlizadeh @StefanAlig @Tessoulin_B
0
9
31
#JournéeMondialedesLymphomes 📣 #JMLs2022 organisée par @AssoELLyE et soutenue par @LysaLymphoma 🎯 Informer sur la maladie, et sensibiliser le grand public sur le 1er #cancerdusang à travers des réunions d’information dans 22 villes en France #MoisDesCancersDuSang #JML2022 #JMLS
0
8
8
EHA Abs#S262, CART ttmt finally taking-off for patients suffering of PTCL. A CD70 directed allogeneic CART(CTX130). 80% ORR at higher doses, and a chance to bridge to Allografting.
0
2
6
The reward for a 6am bike ride in winter is the stunning #sunrise in this case the view from @kingspark_wa over #perth #perthisok photo credit: Mark Johnson
3
1
23
Really chuffed to share our latest work from Sanjana Lab out in @nature today ( https://t.co/skHTGrKACw). We tested >12,000 genes to find positive regulators of T cell proliferation to be used for next-gen #immunotherapies. A thread...
25
259
1K
#Nomination | « Par ses valeurs et son histoire, l’Institut Curie porte une profonde dimension humaniste que je m’engage à poursuivre. » A compter du 1er septembre, le Pr Steven Le Gouill 🧑⚕️ prend la direction de l’Ensemble Hospitalier de l’Institut Curie. ⬇️
4
7
28
Excited for the opportunities to apply this next generation of MRD technologies for more sensitive detection of lymphomas and other cancers.
#16ICML David Kurtz and @AshAlizadeh group, PhasED Seq more sensitive and specific for MRD testing in DLBCL. Potential for MRD adapted and personalized approach to lymphoma therapy.
0
2
18
Excited to share our recent work with @tanaya_shree in @BloodJournal on divergent evolution in lymphoma. Grateful for mentorship by Ron Levy and the collaboration with the Hanlee Ji lab & all coauthors including Anuja Sathe & @gradycday #lymsm @StanfordMed
https://t.co/ueZvTv3qDW
0
6
21
Very excited to share our new study out today in @JCO_ASCO, deciphering the biological basis for the Diagnosis to Treatment Interval (DTI) in lymphoma and relationship to #ctDNA tumor burden. #lymsm
https://t.co/4Jm6R6t4XK
ascopubs.org
PURPOSEPatients with Diffuse Large B-cell Lymphoma (DLBCL) in need of immediate therapy are largely under-represented in clinical trials. The diagnosis-to-treatment interval (DTI) has recently been...
1
27
85
On the universality of facial expressions (and emotions): occurrence of 16 expressions in 6M videos from 144 countries was examined using machine learning; facial expressions had distinct associations with a set of contexts. https://t.co/ie93jPWQCX via @nature Inventive and cool.
12
77
276
Dans ma BAL, don du voisinage pour @CHUnantes des petits gestes reconfortants #solidarité avec les soignants #civilité
0
3
11
Here is #ASH16 #leonardlist 8 Abst 145 LeGouill Survival benefit of maint rituximab post SCT mantle cell #lymphoma
2
11
13
7 Substances Added to 14th Report on Carcinogens, especially viruses linked to lymphomas. No news but official.
0
2
0